Long-term use of cardiovascular drugs challenges for research and for patient care

Journal of the American College of Cardiology

Volumn 66, Issue 11, 2015, Pages 1273-1285

  Rossello, Xavier ^a,b   Pocock, Stuart J ^a,c   Julian, Desmond G ^d  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

cardiovascular medications; deprescribing; elderly; long term treatment; polypharmacy; randomized clinical trials

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PYRROLE; SULFONYLUREA; CARDIOVASCULAR AGENT;

ACUTE KIDNEY FAILURE; ADVERSE OUTCOME; AGING; BRONCHOSPASM; CARDIOVASCULAR RISK; CLAUDICATION; CLINICAL PRACTICE; CLINICAL STUDY; CONFUSION; COUGHING; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; DYSPEPSIA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; HYPOTENSION; INCONTINENCE; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIVER TOXICITY; LONG TERM CARE; MYALGIA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SKIN MANIFESTATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TINNITUS; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION; MEDICAL RESEARCH; MYOCARDIAL INFARCTION; PATIENT CARE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRENDS;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; BIOMEDICAL RESEARCH; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; PATIENT CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84941106330     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.07.018     Document Type: Review

References (81)

1. Antithrombotic Trialists' (ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
2. Cholesterol Treatment Trialists' Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
3. M.J. Domanski, D.V. Exner, C.B. Borkowf, and et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials J Am Coll Cardiol 33 1999 598 604
4. M.H. Al-Mallah, I.M. Tleyjeh, A.A. Abdel-Latif, and et al. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials J Am Coll Cardiol 47 2006 1576 1583
5. N. Freemantle, J. Cleland, P. Young, and et al. β Blockade after myocardial infarction: systematic review and meta regression analysis BMJ 318 1999 1730 1737
6. D.G. Julian, and S.J. Pocock Effects of long-term use of cardiovascular drugs Lancet 385 2015 325
7. P.T. O'Gara, F.G. Kushner, D.D. Ascheim, and et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e140
8. S.D. Fihn, J.M. Gardin, J. Abrams, and et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J Am Coll Cardiol 60 2012 e44 e164
9. E.A. Amsterdam, N.K. Wenger, R.G. Brindis, and et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 64 2014 e139 e228
10. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
11. F.M. Sacks, M.A. Pfeffer, L.A. Moye, et al. for the Cholesterol and Recurrent Events Trial Investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
12. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
13. M.C. Odden, M.J. Pletcher, P.G. Coxson, and et al. Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States Ann Intern Med 162 2015 533 541
14. N. Sattar, D. Preiss, H.M. Murray, and et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
15. S.C. Smith Jr., E.J. Benjamin, R.O. Bonow, and et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Foundation and the Preventive Cardiovascular Nurses Association J Am Coll Cardiol 58 2011 2432 2446
16. ACE Inhibitor Myocardial Infarction Collaborative Group Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials Circulation 97 1998 2202 2212
17. PEACE Trial Investigators Angiotensin-converting-enzyme inhibition in stable coronary artery disease N Engl J Med 351 2004 2058 2068
18. E. Sorbets, J. Labreuche, T. Simon, and et al. Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure Eur Heart J 35 2014 1760 1768
19. J.M. Castellano, G. Sanz, J.L. Peñalvo, and et al. A polypill strategy to improve adherence: results from the FOCUS project J Am Coll Cardiol 64 2014 2071 2082
20. Working Group on the Summit on Combination Therapy for CVD Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges Eur Heart J 35 2014 353 364
21. M.P. Bonaca, D.L. Bhatt, M. Cohen, et al. for the PEGASUS-TIMI 54 Steering Committee and Investigators Long-term use of ticagrelor in patients with prior myocardial infarction N Engl J Med 372 2015 1791 1800
22. T. Jernberg, P. Hasvold, M. Henriksson, and et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective Eur Heart J 36 2015 1163 1170
23. P.C. Elwood, A.L. Cochrane, M.L. Burr, and et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction BMJ 1 1974 436 440
24. Coronary Drug Project Research Group Aspirin in coronary heart disease J Chronic Dis 29 1976 625 642
25. P.C. Elwood, and P.M. Sweetnam Aspirin and secondary mortality after myocardial infarction Lancet 2 1979 1313 1315
26. Persantine-Aspirin Reinfarction Study Research Group Persantine and aspirin in coronary heart disease Circulation 62 1980 449 461
27. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction JAMA 243 1980 661 669
28. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
29. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico) Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital Heart J 1 2000 810 820
30. P.W.J.C. Serruys, P. de Feyter, C. Macaya, et al. for the Lescol Intervention Prevention Study (LIPS) Investigators Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial JAMA 287 2002 3215 3222
31. M.J. Koren, and D.B. Hunninghake Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study J Am Coll Cardiol 44 2004 1772 1779
32. C.P. Cannon, E. Braunwald, C.H. McCabe, et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
33. J.A. De Lemos, M.A. Blazing, S.D. Wiviott, et al. for the A to Z Investigators Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
34. J.C. LaRosa, S.M. Grundy, D.D. Waters, et al. for the Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
35. T.R. Pedersen, O. Faergeman, J.J.P. Kastelein for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
36. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
37. Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. A multicentre international study BMJ 3 1975 735 740
38. D.G. Julian, R.J. Prescott, F.S. Jackson, and et al. Controlled trial of sotalol for one year after myocardial infarction Lancet 319 1982 1142 1147
39. European Infarction Study Group European Infarction Study (E.I.S.): a secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality Eur Heart J 5 1984 189 202
40. K.S. Salathia, J.M. Barber, E.L. McIlmoyle, and et al. Very early intervention with metoprolol in suspected acute myocardial infarction Eur Heart J 6 1985 190 198
41. Lopressor Intervention Trial Research Group The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction Eur Heart J 8 1987 1056 1064
42. CAPRICORN Investigators Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial Lancet 357 2001 1385 1390
43. M.A. Pfeffer, E. Braunwald, L.A. Moyé, and et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial N Engl J Med 327 1992 669 677
44. L. Køber, C. Torp-Pedersen, J.E. Carlsen, et al. for the Trandolapril Cardiac Evaluation (TRACE) Study Group A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 333 1995 1670 1676
45. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure Lancet 342 1993 821 828
46. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction Lancet 345 1995 669 685
47. B. Pitt, B. O'Neill, R. Feldman, et al. for the QUIET Study Group The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function Am J Cardiol 87 2001 1058 1063
48. S.E. Nissen, E.M. Tuzcu, P. Libby, et al. for the CAMELOT Investigators Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial JAMA 292 2004 2217 2225
49. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 362 2003 782 788
50. F. Pedersen, V. Butrymovich, H. Kelbæk, and et al. Short- and long-term cause of death in patients treated with primary PCI for STEMI J Am Coll Cardiol 64 2014 2101 2108
51. S.J. Kernis, K.J. Harjai, G.W. Stone, and et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 43 2004 1773 1779
52. S. Bangalore, G. Steg, P. Deedwania, et al. for the REACH Registry Investigators β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease JAMA 308 2012 1340 1349
53. E. Antman, J.P. Bassand, W. Klein, and et al. Myocardial infarction redefined- A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction J Am Coll Cardiol 36 2000 959 969
54. K. Thygesen, J.S. Alpert, H.D. White for the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction Universal definition of myocardial infarction J Am Coll Cardiol 50 2007 2173 2195
55. K. Thygesen, J.S. Alpert, A.S. Jaffe, and et al. Third universal definition of myocardial infarction J Am Coll Cardiol 60 2012 1581 1598
56. M.E.T. McMurdo, H. Roberts, S. Parker, et al. for the Age and Ageing Specialty Group NIHR, Comprehensive Clinical Research Network Improving recruitment of older people to research through good practice Age Ageing 40 2011 659 665
57. M.A. Pfeffer, J.J.V. McMurray, E.J. Velazquez, et al. for the Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906
58. K. Fox, I. Ford, P.G. Steg, et al. for the SIGNIFY Investigators Ivabradine in stable coronary artery disease without clinical heart failure N Engl J Med 371 2014 1091 1099
59. K. Swedberg, M. Komajda, M. Böhm, et al. for the SHIFT Investigators Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study Lancet 376 2010 875 885
60. K. Fox, I. Ford, P.G. Steg, et al. for the BEAUTIFUL Investigators Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 807 816
61. D.W. Kaufman, J.P. Kelly, L. Rosenberg, and et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey JAMA 287 2002 337 344
62. C.J. Charlesworth, E. Smit, D.S.H. Lee, and et al. Polypharmacy among adults aged 65 years and older in the United States: 1988-2010 J Gerontol A Biol Sci Med Sci 70 2015 989 995
63. M. Volpe, D. Chin, and F. Paneni The challenge of polypharmacy in cardiovascular medicine Fundam Clin Pharmacol 24 2010 9 17
64. D.M. Qato, G.C. Alexander, R.M. Conti, and et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States JAMA 300 2008 2867 2878
65. J.H. Gurwitz, T.S. Field, L.R. Harrold, and et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting JAMA 289 2003 1107 1116
66. R.A. Payne, A.J. Avery, M. Duerden, and et al. Prevalence of polypharmacy in a Scottish primary care population Eur J Clin Pharmacol 70 2014 575 581
67. J.L. Fleg, W.S. Aronow, and W.H. Frishman Cardiovascular drug therapy in the elderly: benefits and challenges Nat Rev Cardiol 8 2011 13 28
68. A.P. DeFilippis, R. Young, C.J. Carrubba, and et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort Ann Intern Med 162 2015 266 275
69. A.M. Navar-Boggan, E.D. Peterson, R.B. D'Agostino, and et al. One size may not fit all: using age- and sex-specific risk thresholds to guide statin therapy J Am Coll Cardiol 65 2015 1633 1639
70. O. Mukhtar, and S.H. Jackson Drug therapies in older adults (part 1) Clin Med 15 2015 47 53
71. A.A. Mangoni, and S.H.D. Jackson Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications Br J Clin Pharmacol 57 2004 6 14
72. M. Fralick, E.M. Macdonald, T. Gomes, et al. for the Canadian Drug Safety and Effectiveness Research Network (CDSERN) Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study BMJ 349 2014 g6196
73. R.M. Seymour, and P.A. Routledge Important drug-drug interactions in the elderly Drugs Aging 12 1998 485 494
74. P.M. Rothwell External validity of randomised controlled trials: to whom do the results of this trial apply? Lancet 365 2005 82 93
75. P.Y. Lee, K.P. Alexander, B.G. Hammill, and et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes JAMA 286 2001 708 713
76. D. Gnjidic, D.G. Le Couteur, and S.N. Hilmer Discontinuing drug treatments BMJ 349 2014 g7013
77. S.J. Pocock, and B.J. Gersh Do current clinical trials meet society's needs? A critical review of the evidence J Am Coll Cardiol 64 2014 1615 1628
78. G. Giustino, U. Baber, S. Sartori, and et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials J Am Coll Cardiol 65 2015 1298 1310
79. L. Mauri, D.J. Kereiakes, R.W. Yeh, et al. for the DAPT Study Investigators Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents N Engl J Med 371 2014 2155 2166
80. M.C. Kim, J.Y. Cho, H.C. Jeong, and et al. Impact of postdischarge statin withdrawal on long-term outcomes in patients with acute myocardial infarction Am J Cardiol 115 2015 1 7
81. M. Lordkipanidzé, J.G. Diodati, and C. Pharand Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence Pharmacol Ther 123 2009 178 186